Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors—originally developed for the treatment of T2DM—have undergone mandatory cardiovascular safety trials during their development. Here, SLC5A2 is linked to type 2 diabetes mellitus.